China Resources Pharmaceutical Group Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 5/6
China Resources Pharmaceutical Group has been growing earnings at an average annual rate of 4.3%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 8% per year. China Resources Pharmaceutical Group's return on equity is 8.5%, and it has net margins of 1.5%.
Wichtige Informationen
4.3%
Wachstumsrate der Gewinne
4.4%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 5.6% |
| Wachstumsrate der Einnahmen | 8.0% |
| Eigenkapitalrendite | 8.5% |
| Netto-Marge | 1.5% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up
Oct 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17Aufschlüsselung der Einnahmen und Ausgaben
Aufschlüsselung der Einnahmen und Ausgaben
Wie China Resources Pharmaceutical Group Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 250,483 | 3,777 | 25,588 | 0 |
| 31 Mar 24 | 247,593 | 3,816 | 25,420 | 0 |
| 31 Dec 23 | 244,704 | 3,854 | 25,252 | 0 |
| 30 Sep 23 | 232,564 | 3,573 | 23,906 | 0 |
| 30 Jun 23 | 224,656 | 3,382 | 22,961 | 0 |
| 31 Mar 23 | 224,587 | 3,518 | 22,783 | 0 |
| 31 Dec 22 | 218,183 | 3,500 | 21,999 | 0 |
| 30 Sep 22 | 221,487 | 3,724 | 22,247 | 0 |
| 30 Jun 22 | 211,788 | 3,719 | 21,193 | 0 |
| 31 Mar 22 | 196,226 | 3,288 | 19,674 | 0 |
| 31 Dec 21 | 193,021 | 3,072 | 19,393 | 0 |
| 30 Sep 21 | 191,495 | 2,869 | 19,667 | 0 |
| 30 Jun 21 | 187,554 | 2,626 | 19,701 | 0 |
| 31 Mar 21 | 179,512 | 2,720 | 19,092 | 0 |
| 31 Dec 20 | 168,762 | 2,776 | 18,197 | 0 |
| 30 Sep 20 | 171,873 | 2,683 | 19,137 | 0 |
| 30 Jun 20 | 174,956 | 2,578 | 20,122 | 0 |
| 31 Mar 20 | 181,054 | 2,793 | 21,233 | 0 |
| 31 Dec 19 | 182,690 | 2,937 | 21,813 | 0 |
| 30 Sep 19 | 183,417 | 3,670 | 21,984 | 0 |
| 30 Jun 19 | 173,938 | 4,187 | 20,930 | 0 |
| 31 Mar 19 | 165,679 | 3,737 | 20,069 | 0 |
| 31 Dec 18 | 166,626 | 3,494 | 20,322 | 0 |
| 30 Sep 18 | 163,734 | 3,466 | 19,540 | 0 |
| 30 Jun 18 | 154,852 | 3,309 | 18,062 | 0 |
| 31 Mar 18 | 142,296 | 2,959 | 15,795 | 0 |
| 31 Dec 17 | 143,688 | 2,901 | 15,087 | 0 |
| 30 Sep 17 | 143,252 | 2,759 | 14,277 | 0 |
| 30 Jun 17 | 142,276 | 2,602 | 13,380 | 0 |
| 31 Mar 17 | 142,003 | 2,577 | 13,395 | 0 |
| 31 Dec 16 | 140,316 | 2,526 | 13,279 | 0 |
| 30 Sep 16 | 132,253 | 2,161 | 12,534 | 0 |
| 30 Jun 16 | 129,313 | 1,889 | 12,274 | 0 |
| 31 Mar 16 | 123,770 | 2,103 | 11,766 | 0 |
| 31 Dec 15 | 122,785 | 2,388 | 11,692 | 0 |
| 31 Dec 14 | 108,575 | 2,116 | 9,955 | 0 |
| 31 Dec 13 | 91,313 | 2,061 | 9,248 | 0 |
Qualität der Erträge: 3320 has high quality earnings.
Wachsende Gewinnspanne: 3320's current net profit margins (1.5%) are higher than last year (1.5%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 3320's earnings have grown by 4.3% per year over the past 5 years.
Beschleunigtes Wachstum: 3320's earnings growth over the past year (11.7%) exceeds its 5-year average (4.3% per year).
Erträge im Vergleich zur Industrie: 3320 earnings growth over the past year (11.7%) exceeded the Pharmaceuticals industry 6.4%.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 3320's Return on Equity (8.5%) is considered low.